Sacubitril/Valsartan Sodium Hydrate

沙库巴曲/缬沙坦钠

Report date: 2026/05/25 20:02:40
First In Class

Base Information

Drug NameSacubitril/Valsartan Sodium Hydrate
Drug Alias NameSacubitril and Valsartan Sodium Hydrate缬沙坦/沙库巴曲sacubitril + valsartan trisodium hemipentahydrate沙库巴曲缬沙坦钠沙库巴曲+缬沙坦 +[18] 
ClassificationSmall molecules
Mechanisms of ActionNeprilysin inhibitorsAngiotensin II Receptor Type 1 antagonists
TargetsAngiotensin II Receptor Type 1Neprilysin
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)ObesityEssential Hypertension +[21] 
Global Approved IndicationsHeart Failure
Approved Indications in ChinaHeart Failure
Original Approved Country/TerritoryUnited States
Original Approved Date2015/07/07
Country/TerritoryCzechiaBelgiumBulgaria +[64] 
CombinationsYes ValsartanSacubitril
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesInstitute For Cardiovascular Diseases Of VojvodinaBio-innova Co LtdDr. Reddy's Laboratories (Thailand) Ltd +[18] 
Inactive CompaniesNovartis Ireland LtdUniversity Of MinnesotaNovartis Pharma Stein Ag +[6] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)ObesityEssential Hypertension +[10] 
Inactive IndicationsPeripheral Arterial DiseaseVentricular Dysfunction, LeftMyocardial Infarction +[11] 

Other Information

ATC CodeC09DX04
Related LinksN/A